Tomer Cohen

Company: KAHR Medical

Job title: Chief Business Officer

Seminars:

Learning from DSP107, a CD47x4-1BB bi-specific, to Advance Therapies into the Future & Consider the Continued Therapeutic Potential of CD47 11:30 am

Improving target specificity and activity using bi-specific fusion protein Transforming safety profile and avoiding hematological toxicities Enhancing the treatment potential of solid and hematological malignanciesRead more

day: Conference Day One